CTOs on the Move

Brii Biosciences

www.briibio.com

 
Brii Biosciences (Brii Bio) is a company committed to serving patients` needs and improving public health in China. Founded in early 2018, the company focuses on accelerating innovation and optimizing access to the latest medicines for Chinese patients. Brii Bio helps global partners drive growth and improve return on investment through better understanding of Chinese healthcare systems and access to the world`s second largest pharmaceutical market. The company`s focus is treatments for chronic illnesses with significant burdens, including infectious diseases, liver and lung diseases, and other illnesses. The company is headquartered in the People`s Republic of China and the United ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.briibio.com
  • One City Center 110 Corcoran Street Office 05-110
    Durham, NC USA 27701
  • Phone: 919.240.5605

Executives

Name Title Contact Details
Eleanor de Groot
Chief Technology Officer Profile

Funding

Brii Biosciences raised $155M on 03/23/2021

Similar Companies

Affinia Therapeutics

We are working to methodically engineer durable gene therapies for people with devastating diseases.

FerGene

FerGene is a new gene therapy company dedicated to creating and delivering innovative solutions to urologists and those affected by non-muscle invasive bladder cancer (NMIBC).

Arcutis

Arcutis was founded in 2016 to address significant unmet needs in medical dermatology. The company is a clinical-stage biopharmaceutical company focused on developing and commercializing best-in-class products. Our strategy is to exploit recent innovations in inflammation and immunology to bring the best molecules to bear against validated physiologic targets known to treat dermatological diseases and disorders. Our management team has extensive expertise in the development and commercialization of medical dermatology products, having held key leadership roles at a number of leading dermatology companies and, collectively, has successfully developed more than 50 FDA-approved products. We believe that by leveraging our team`s unique experience and demonstrated expertise to identify, develop and commercialize best-in-class molecules against validated targets, we will be able to develop differentiated products in less time, at lower cost, and at substantially lower risk than other approaches. Arcutis` combination of vision, unmet medical need, experienced management and strategic approach has attracted support from leading investors in the life sciences sector.

Connect Biopharma

Connect Biopharma (Nasdaq: CNTB) is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research. With operations and expertise in China, the United States and Australia and clinical development activities in those geographies as well as Europe, Connect Biopharma is building a rich pipeline of internally designed, wholly owned small molecules and antibodies targeting several aspects of T cell biology. Our core expertise is in the use of functional cellular assays with T cells to screen and discover potent drug candidates against immune targets. Our two most advanced clinical-stage programs include highly differentiated product candidates against validated targets.

PathoGenetix

PathoGenetix is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.